1991-2919

The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation

SCEEMP

View prefix report (10.30895)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 54 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact54 DOIs
2

Deposit reference lists for 41 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact41 DOIs
3

Attach ORCID iDs across 26 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact26 DOIs

DOIs for this ISSN

Showing the top 5 of 207 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Criteria for Assessment of Cognitive Impairment in Clinical… (10.30895/1991-2919-2018-8-4-218-230)
Abstract
35.78 26
2 Relevant Aspects of Standardisation of Plant Raw Materials a… (10.30895/1991-2919-2022-12-2-127-141)
Abstract
25.00 9
3 “There is a great future for radiopharmaceuticals in Russian… (10.30895/1991-2919-2022-12-4-359-361)
References ORCID
23.86 2
4 Current Trends in the Study of Promising Medicinal Plant Spe… (10.30895/1991-2919-2024-14-2-128-131)
References ORCID
23.86 2
5 Quality Standards of Preclinical Pharmacological Studies (10.30895/1991-2919-2019-9-4-248-255)
Abstract
19.45 5
6 Comparison of the Nomenclatures of Herbal Substances Used in… (10.30895/1991-2919-2020-10-1-29-40)
Abstract
19.45 5
7 Regulation of Radiopharmaceutical Products (10.30895/1991-2919-2022-12-4-379-388)
Abstract
19.45 5
8 Development of a Comprehensive Approach to Assessing the Con… (10.30895/1991-2919-2022-12-2-149-160)
Abstract
17.47 4
9 Analysis of the Main Changes in Assessment and Approval of M… (10.30895/1991-2919-2022-12-2-222-226)
Abstract
17.47 4
10 Analysis of the provisions of national and EAEU legislation… (10.30895/1991-2919-2023-13-4-586-600)
References
17.47 4
11 Recommendations on the EAEU Marketing Authorisation Procedur… (10.30895/1991-2919-2023-544)
References
17.47 4
12 Harmonisation of Russian and Foreign Pharmacopoeial Standard… (10.30895/1991-2919-2020-10-3-184-191)
Abstract
15.05 3
13 Recommendations on Describing the Requirements for Microbiol… (10.30895/1991-2919-2022-12-2-120-123)
Abstract References
15.05 1
14 “We should strive to attain Russia’s former standing in nucl… (10.30895/1991-2919-2022-12-4-356-358)
References ORCID
15.05 1
15 Radioactivity distribution in the blood and urine of patient… (10.30895/1991-2919-2022-12-4-404-414)
Abstract
15.05 3
16 Nasolacrimal Duct Obstruction Secondary to Radioactive Iodin… (10.30895/1991-2919-2022-12-4-415-424)
Abstract
15.05 3
17 Post-approval Variations to Dossiers for Vaccines: Analysis… (10.30895/1991-2919-2019-9-1-41-48)
Abstract
11.93 2
18 Planning a Clinical Development Programme for Medicines for… (10.30895/1991-2919-2021-11-1-55-69)
Abstract
11.93 2
19 Harmonisation of Pharmacopoeial Requirements for Identificat… (10.30895/1991-2919-2022-12-2-142-148)
Abstract
11.93 2
20 The Main Aspects of End-to-End Standardisation of Herbal Dru… (10.30895/1991-2919-2022-12-2-183-192)
Abstract
11.93 2
21 Quantitative clinical pharmacology and patient-centered heal… (10.30895/1991-2919-2022-12-2-205-213)
Abstract
11.93 2
22 Control of Residual Organic Solvents in Active Substances (10.30895/1991-2919-2022-12-3-241-243)
References
11.93 2
23 Peculiarities of the Regulatory Status of Radiopharmaceutica… (10.30895/1991-2919-2022-12-4-389-394)
Abstract
11.93 2
24 Pharmacokinetic Studies of Radiopharmaceuticals (10.30895/1991-2919-2022-12-4-395-403)
Abstract
11.93 2
25 Features and Practical Aspects of Radiochemical Purity Deter… (10.30895/1991-2919-2022-12-4-455-467)
Abstract
11.93 2
26 Planning of a Clinical Data Registry for Basic Anti-Inflamma… (10.30895/1991-2919-2018-8-4-238-245)
Abstract
7.53 1
27 Use of Biomarkers in Pharmacokinetics Studies of Medicinal P… (10.30895/1991-2919-2021-11-1-24-35)
Abstract
7.53 1
28 Recommendations for the Contents of the “Peptide Mapping” Pa… (10.30895/1991-2919-2021-11-4-276-277)
References
7.53 1
29 Improvement of Methods for Standardisation of Medicines Base… (10.30895/1991-2919-2022-12-2-161-172)
Abstract
7.53 1
30 Inductively Coupled Plasma-Atomic Emission Spectrometry for… (10.30895/1991-2919-2022-12-2-173-182)
Abstract
7.53 1
31 The Content of Heavy Metals, Arsenic, and Aluminum in Mint L… (10.30895/1991-2919-2022-12-2-408)
Abstract
7.53 1
32 Control of the Purity of 93% Oxygen Obtained from the Air b… (10.30895/1991-2919-2022-12-3-310-314)
References
7.53 1
33 Potential of Theranostics in Visualisation of the Tumour Mic… (10.30895/1991-2919-2022-12-4-425-443)
Abstract
7.53 1
34 Preparation of Module 1 of the Registration Dossier Accordi… (10.30895/1991-2919-2022-12-467)
References
7.53 1
35 Radioisotope Products and the Medicine of the Future: an IAE… (10.30895/1991-2919-2022-423)
Abstract
7.53 1
36 Russian regulatory system for clinical trials is consistent… (10.30895/1991-2919-2023-13-4-488-492)
References
7.53 1
37 The International Pharmacopoeia: Focus, Processes, Response… (10.30895/1991-2919-2023-455)
References
7.53 1
38 Actions of the Manufacturers of Herbal and Other High-Demand… (10.30895/1991-2919-2024-14-2-132-137)
References
7.53 1
39 Improvement of Methods of Standardisation of Medicinal Produ… (10.30895/10.30895/1991-2919-2021-11-1-44-48)
0.00 0
40 Determination of the Biological Activity of Insulin and Its… (10.30895/10.30895/1991-2919-2022-403)
0.00 0
41 INFORMATION SYSTEM FOR EXPERT EVALUATION OF MEDICINES INTERC… (10.30895/1991-2919-2018-8-2-99-102)
0.00 0
42 Current Requirements for and Approaches to Dosing in Animal… (10.30895/1991-2919-2018-8-4-207-217)
0.00 10
43 Planning and Evaluation of Bioequivalence Studies of Enalapr… (10.30895/1991-2919-2018-8-4-231-237)
Abstract
0.00 0
44 Interchangeability of Fluconazole Drugs (10.30895/1991-2919-2018-8-4-246-251)
0.00 0
45 Comparative Evaluation of Assay Methods Used to Determine An… (10.30895/1991-2919-2018-8-4-252-261)
0.00 1
46 Improvement of Tests for the Control of Impurities in Antimi… (10.30895/1991-2919-2018-8-4-262-270)
Abstract
0.00 0
47 Approaches to Clinical Development of Combination Medicines… (10.30895/1991-2919-2019-9-1-14-27)
0.00 2
48 Regulatory Requirements of the European Medicines Agency for… (10.30895/1991-2919-2019-9-1-28-33)
0.00 0
49 Criteria for Evaluation of Clinical Efficacy of Anticancer M… (10.30895/1991-2919-2019-9-1-34-40)
0.00 3
50 Conceptualisation of an Information Analytical Database of… (10.30895/1991-2919-2019-9-1-49-53)
0.00 2